

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 9, 2021

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

She-Chia Chen, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Philip C. Hoffman, MD

(Chairperson)
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

David E. Mitchell

(Consumer Representative)
Founder, Patients for Affordable Drugs
Bethesda, Maryland

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Albert L. Kraus, PhD

Global Regulatory Portfolio Lead, Oncology
Pfizer, Inc.
Guilford, Connecticut

TEMPORARY MEMBERS (Voting)

Deborah K. Armstrong, MD

Professor of Oncology
Professor of Gynecology and Obstetrics
The Skip Viragh Outpatient Cancer Building
Director, Breast and Ovarian Surveillance Service
Johns Hopkins Sidney Kimmel Comprehensive
Cancer Center
Baltimore, Maryland

Matthew Ellis, MD, PhD

Professor and Breast Center Director
Baylor College of Medicine
Houston, Texas

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 9, 2021

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Daniel F. Hayes, MD, FASCO, FACP

Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Stan Lipkowitz, MD, PhD

Chief, Women's Malignancies Branch
Center for Cancer Research, National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Natalie Compagni Portis, PsyD, MFT

(Patient Representative)
Oakland, California

Andrew D. Seidman, MD

Attending Physician, Breast Medicine Service
Medical Director, Bobst International Center
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York City, New York

Antonio C. Wolff, MD, FACP, FASCO

Professor of Oncology
Director, Breast Cancer Trials
Johns Hopkins University Kimmel Cancer Center
Baltimore, Maryland

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Acting Director, Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Julia Beaver, MD

Chief of Medical Oncology, OCE
Deputy Director (acting)
OOD, OND, CDER, FDA

Laleh Amiri-Kordestani, MD

Director, Division of Oncology 1 (DO1)
OOD, OND, CDER, FDA

Christy Osgood, MD

Cross-Discipline Team Leader
Breast and Gynecologic Malignancies Team
DO1, OOD, OND, CDER, FDA

Mirat Shah, MD

Clinical Reviewer
Breast and Gynecologic Malignancies Team
DO1, OOD, OND, CDER, FDA

Mallorie Fiero, PhD

Statistical Team Leader
Division of Biometrics V (DBV)
Office of Biostatistics (OB)
Office of Translational Sciences (OTS)
CDER, FDA

Anup Amatya, PhD

Statistical Reviewer
DBV, OB, OTS, CDER, FDA